News

New Two-Year Follow-Up Of Roche’S Columvi Extends Overall Survival In Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Patients
Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall surviva ...